Hikal Ltd
HIKAL
Company Profile
Business description
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
Contact
Great Eastern Chambers
6th Floor, Sector 11, CBD Belapur
Navi MumbaiMH400 614
INDT: +91 2262770299
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
3,595
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,161.78 | 26.81 | -0.33% |
| DAX 40 | 24,113.83 | 282.84 | 1.19% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,391.53 | 36.96 | 0.40% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |